Skip to Content
 

News: Immunotherapy

Journey Home Project supports first CAR-T infusion at VA hospital

Thursday, January 16th, 2020

The Tennessee Valley Healthcare System performed its first CAR-T infusion recently at the Veterans Administration hospital in Nashville.

Project seeks new way to assess immunotherapy effectiveness

Thursday, November 7th, 2019

GE Healthcare has awarded researchers $2.5 million in funding to develop PET tracer that will determine the effectiveness of immunotherapy in patients early in their treatment course.

New prostate cancer treatment concept

Friday, August 30th, 2019

Combining immunotherapy and radiation therapy may be a powerful treatment approach for castration-resistant prostate cancer.

Encephalitis identified as rare toxicity of immunotherapy treatment

Monday, July 22nd, 2019

Researchers are chronicling rare but serious toxicities that may occur with immune checkpoint inhibitors, the most widely prescribed class of immunotherapies.

Study identifies critical regulator of tumor-specific T cell differentiation

Saturday, June 29th, 2019

A study published June 17 in Nature offers clues as to why blocking inhibitory receptors on tumor-infiltrating T cells may not always work

Immunotherapy helping 87-year-old man stay on the job

Friday, June 7th, 2019

Immunotherapy is helping cancer patient Roszell Mack Jr. to continue going to his job on a Kentucky horse farm.

VICC launches new telehealth program for CAR-T patients

Monday, March 4th, 2019

Some cancer patients receiving CAR-T infusions can now avoid hospital stays because of a telemedicine program launched by Vanderbilt-Ingram Cancer Center.

Discovery points to new cancer immunotherapy option

Monday, February 25th, 2019

Researchers have discovered that a new “checkpoint” protein on immune system cells is active in tumors, and that blocking it — in combination with other treatments — is a successful therapeutic approach in mouse models of cancer.

Research team documents potential new treatment path for breast cancer

Friday, January 18th, 2019

Immunotherapies that take off the “brakes” on the adaptive anti-tumor response have worked well in melanoma and lung cancer but less so in breast cancers. That could change.

Breast cancer-killing RIG

Friday, December 14th, 2018

A recent study in the journal Cancer Research demonstrates that a RIG-I agonist has potent immunogenic and therapeutic effects in breast cancer.

Next Page »